Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T00238
|
||||
Former ID |
TTDI02298
|
||||
Target Name |
mRNA of Nuclear factor kappa B
|
||||
Gene Name |
NFKB2
|
||||
Synonyms |
DNAbinding factor KBF2 (mRNA); H2TF1 (mRNA); Lymphocyte translocation chromosome 10 protein (mRNA); Lyt10 (mRNA); NFKB2 (mRNA); Nuclear factor NFkappaB p100 subunit (mRNA); Nuclear factor NFkappaB p52 subunit (mRNA); Nuclear factor of kappa light polypeptide gene enhancer in Bcells 2 (mRNA); Oncogene Lyt10 (mRNA); NFKB2
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Ulcerative colitis [ICD9: 556; ICD10: K51] | ||||
Function |
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF- kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14- activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation ofp52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK- ARNTL/BMAL1 heterodimer.
|
||||
BioChemical Class |
Target of antisense drug
|
||||
UniProt ID | |||||
Sequence |
MESCYNPGLDGIIEYDDFKLNSSIVEPKEPAPETADGPYLVIVEQPKQRGFRFRYGCEGP
SHGGLPGASSEKGRKTYPTVKICNYEGPAKIEVDLVTHSDPPRAHAHSLVGKQCSELGIC AVSVGPKDMTAQFNNLGVLHVTKKNMMGTMIQKLQRQRLRSRPQGLTEAEQRELEQEAKE LKKVMDLSIVRLRFSAFLRASDGSFSLPLKPVISQPIHDSKSPGASNLKISRMDKTAGSV RGGDEVYLLCDKVQKDDIEVRFYEDDENGWQAFGDFSPTDVHKQYAIVFRTPPYHKMKIE RPVTVFLQLKRKRGGDVSDSKQFTYYPLVEDKEEVQRKRRKALPTFSQPFGGGSHMGGGS GGAAGGYGGAGGGGSLGFFPSSLAYSPYQSGAGPMGCYPGGGGGAQMAATVPSRDSGEEA AEPSAPSRTPQCEPQAPEMLQRAREYNARLFGLAQRSARALLDYGVTADARALLAGQRHL LTAQDENGDTPLHLAIIHGQTSVIEQIVYVIHHAQDLGVVNLTNHLHQTPLHLAVITGQT SVVSFLLRVGADPALLDRHGDSAMHLALRAGAGAPELLRALLQSGAPAVPQLLHMPDFEG LYPVHLAVRARSPECLDLLVDSGAEVEATERQGGRTALHLATEMEELGLVTHLVTKLRAN VNARTFAGNTPLHLAAGLGYPTLTRLLLKAGADIHAENEEPLCPLPSPPTSDSDSDSEGP EKDTRSSFRGHTPLDLTCSTKVKTLLLNAAQNTMEPPLTPPSPAGPGLSLGDTALQNLEQ LLDGPEAQGSWAELAERLGLRSLVDTYRQTTSPSGSLLRSYELAGGDLAGLLEALSDMGL EEGVRLLRGPETRDKLPSTAEVKEDSAYGSQSVEQEAEKLGPPPEPPGGLCHGHPQPQVH |
||||
Drugs and Mode of Action | |||||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | MAPK signaling pathway | ||||
NF-kappa B signaling pathway | |||||
Osteoclast differentiation | |||||
Legionellosis | |||||
HTLV-I infection | |||||
Epstein-Barr virus infection | |||||
Pathways in cancer | |||||
Viral carcinogenesis | |||||
NetPath Pathway | IL5 Signaling Pathway | ||||
PANTHER Pathway | Apoptosis signaling pathway | ||||
B cell activation | |||||
Inflammation mediated by chemokine and cytokine signaling pathway | |||||
T cell activation | |||||
Toll receptor signaling pathway | |||||
Pathway Interaction Database | IL12-mediated signaling events | ||||
Alternative NF-kappaB pathway | |||||
PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | ||||
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||||
Reactome | RIP-mediated NFkB activation via ZBP1 | ||||
DEx/H-box helicases activate type I IFN and inflammatory cytokines production | |||||
TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||||
Interleukin-1 processing | |||||
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | |||||
IkBA variant leads to EDA-ID | |||||
Dectin-1 mediated noncanonical NF-kB signaling | |||||
NIK--> | |||||
noncanonical NF-kB signaling | |||||
TRAF6 mediated NF-kB activation | |||||
WikiPathways | Toll-like receptor signaling pathway | ||||
DNA Damage Response (only ATM dependent) | |||||
SIDS Susceptibility Pathways | |||||
Cytosolic sensors of pathogen-associated DNA | |||||
TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||||
EBV LMP1 signaling | |||||
TNF alpha Signaling Pathway | |||||
TSLP Signaling Pathway | |||||
Neural Crest Differentiation | |||||
TWEAK Signaling Pathway | |||||
RANKL/RANK Signaling Pathway | |||||
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||||
Interleukin-1 processing | |||||
Folate Metabolism | |||||
Vitamin B12 Metabolism | |||||
Selenium Micronutrient Network | |||||
Regulation of toll-like receptor signaling pathway | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.